Icon
+91 94997 68112
Login Register

Relistor - (12mg/0.6ml; Solution, Subcutaneous)

Methylnaltrexone bromide SALIX Pharma
12mg/0.6ml; Solution, Subcutaneous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has been insufficient
Yes
***** ** *** ***** ** **** **** ** *** ****/*.*** & ***/*.*** ******** ********* **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, **** *** *** ************ *********. ** ****** **** **** ***** ******* ** ***** ****. ******* **** (*******), *** **** ***** **** ** **** **** ******* ** ****/*.*** & ***/*.*** ******** ********* *** *** ************ *********. ** ********** ******* ***** & ****(*******) ***** ***** ****** '*** ** ***** *** ********* **** **** ** *** ******** *** ***** ****** *** *, ****. ** ******** ** ********* **** ******* ** ****** '***. *****, ******* ******* **** ***** ** ******* *****. **** (*******) ** *** ***** ** **** **** ** **** ******** ***** ****** **** ******* ’*** ******, ’*** ******, ’*** ******, ’*** ******, *** ’*** ******. ** ****** **** **** **** (*******) ****** ** *** ****. ****: ***** ******* ** $**** ******** ***** *********** ** ********* ** *** ****, ******* *** ********* ********. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) ********* *** ****** *** *******. *** ******* ******** ****** ****** ** **** *** ***** ** **** *** ***** **** ***** *** *** **** ** ***** ******. ***** ******* ********** **** ***** ***** ***** *** ** ****** '***. *** ***** ** ********** *** *** ***** *** ** *** ****** *** ******* ****** ** ** ** *** **** **** (***** **** ******* **** ******* *** ****** ** *** ****)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
***** ******* ******* *** ** ** ******* ******* *** ********* *** ********* *** ********* **** *** ******
******* ******* ******* *** ** ** ******* ******* *** ********* *** ********* *** ********* *** *********
*** ****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** **, **** ******* ***** *** ** ** ** ****** '*** ********* ******** ** ** ****
******* ** \ ** *** **, **** ******* ***** *** ** ** ** ****** '*** ********* ******** ** *** **, ****
*** ****** ** \ ** *** **, **** ******* **** ** *** **, ****
  1. *** *, **** : ***** ******** ******* ***** *** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  2. *** **, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  3. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****.
  4. *** **, **** : ***** ******** ******* ***** *** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  5. *** *, **** : ******* ***** * **** ******** ******* ** ******** ***** ** **.
  6. *** *, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  7. *** **, **** : ******* ***** * **** ******* *** ** *** ***** **** ** *** ********* ** **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****.
  8. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  9. *** **, **** : ******* ******* **** * ********** *** ******* ********* **** *** ********* ** ***** *** ****** ****** *** ******* ****** *** **, ****.
  10. *** **, **** : **** & ******* ******** ******* ***** ***** **** *** ***** ******** ******* **** ******* ’*** ******, ’*** ******, ’*** ******, ’*** ******, *** ’*** ******
  11. *** **, **** : ******** ***** ***** ** ******* ** ***** ** ******* *** ******* ***** *** ****(*******) ***** ***** ***** ****** '***- *** *, **** ** ***** *** ********* ** ***** *** *******. ***** *** ******* ******** *** ******** ** ******* *******.
  12. *** *, **** : ** ******** ** ********* **** ******* ** ****** '***
  13. *** **, **** : ******* ******* **** ***** ** ******* *****.
  14. *** **, **** : ********** ******** **** *** & ***** *** ******** ********** *** *** *** ******* ** ****.
  15. *** **, **** : ******* *** ********* ********. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)
  16. *** *, **** : ***** ****** ******** ****** ****** ********* *** **** ** ******.
  17. *** **, **** : ****** ****** **** ***** ****** ** ******* '***, '***, '***, '***, '***, '***, '*** *** '***.
  18. *** **, **** : ****** ****** ******* ********** **** ***** ****** ** ******* *****

Relistor - (150 mg; Tablet, Oral)

Methylnaltrexone bromide SALIX Pharma
150 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indications for RELISTOR: Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation
Yes
**** ** ***. **** ***** * **** ** ** *** ******* *** *** *********. ** ****** **** **** **** ******* ** **** ****. *****, ***** ***** **** ******* (***** **, ****) ****** ** ***** *** ********* ** ****. **, ** ******** **** **** **** ****** **** ******* ***** ***** **, ****(*.* ***** ****** ** '*** ******)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
**** ******* ******** *** ** *** **** ** ** ******** *** ** *** ******** *** ** *** ******** *** ** *** ******** *** ** *** ******** *** ** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ** **** *, **** ******* ***** ****** ** ** ********* ******** ******* *** **** *** *** ****
  1. *** *, **** : ****** ****** ***** * **** ******* **** ** ******* '***, '***(**** **, ****) *** '***, '***, '*** (***** **, ****)
  2. *** *, **** : ****** ****** ***** * **** ******* **** ** ******* '***, '*** (**** **, ****)
  3. *** **, **** : ****** ****** ***** * **** ******* **** ** ****** ******** (***** **, ****)
  4. **** **, **** : ***** ***** **** ******* (***** **, ****) ****** ** ***** *** ********* ** ****. **** ******** **** ******** ** **.
  5. *** *, **** : ****** ****** **** * ******** *** ** *** **** (*******) **** ******* '***, '***, '***, '***, '***, *** '***.
  6. *** **, **** : **** (*******) ********* *** ** ****** ******* ****** ******.
  7. *** **, **** : ****** ****** *** **** (*******) ******* ********** **** ****** '*** ** ******* *****.

Relistor - (8mg/ 0.4ml; Solution, Subcutaneous)

Methylnaltrexone bromide SALIX Pharma
8mg/ 0.4ml; Solution, Subcutaneous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, where response to laxative therapy has been insufficient
Yes
***** ** ******** *** ***** ** **** *** **** *** *** ********* ********. ******* *** **** ***** **** **. ***** **** ***** *** ******* **** ** ****** '*** ** **, *** ******** *** ******** ** ******* ***** ***** ** ******. ** *********** ** ********* ********* ******** ** ***** *******. *****, ******* ******* **** ***** ** ******* *****. ** *** ****, ******* *** ********* ********. ********* ** ****** ** **** ****** *** ******* ***** ********** ** '*** ******. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)
Relistor Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
***** *******/*** ********* ******* *******/*** ********* ******* *******/*** ********* **** ** **, ******** ** ** ******* *******/*** *********
******* ******* ******* *** ** ** ******* ******* ******* ******* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** **,**** ******* ***** *** ** ** ********* ******** ****** ***** ****
******* ** \ ** *** **, **** ******* ***** *** ** ** ********* ******** *** ****** *** **, ****
  1. *** **, **** : * **** ** ** *****
  2. *** **, **** : ***** ******** ******* ***** *** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****
  3. *** *, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  4. *** *, **** : ******* ******** ******* ***** *** **** ****** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****, '*** (*** **, ****)
  5. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** *** ********* * **/*.* ** **** ******* '***-*** **, ****, '***-*** **, ****, '***- *** *, ****, '***-*** **, ****, '*** (*** **, ****)
  6. *** **, **** : ***** *** ********* ********
  7. *** **, **** : ******** ***** ***** ** ******* ** ***** ** ******* *** ******* ***** *** ****(*******) ***** ***** ***** ****** '***- *** *, **** ** ***** *** ********* ** ***** *** *******. ***** *** ******* ******** *** ******** ** ******* *******.
  8. *** *, **** : ** ******** ** ********* **** ******* ** ****** '***
  9. *** **, **** : ******* ******* **** ***** ** ******* *****.
  10. *** **, **** : ******* *** ********* ********. ********* ** ****** ** **** ****** *** ******* ***** ********** ** '*** ******. (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***)

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.